Filing Flows › NewAmsterdam Pharma Co N.V. (NAMS) › Q3 2026 › vs Q2 2026
NewAmsterdam Pharma Co N.V. (NAMS) Q3 2026 vs Q2 2026 (quarter over quarter)
NewAmsterdam Pharma Co N.V.'s revenue rose $15.5M (+418%) from $3.7M in Q2 2026 to $19.2M in Q3 2026.
NewAmsterdam Pharma Co N.V., Q3 2026: revenue $19.2M (55× year over year), operating margin -230.6%, net loss $17.4M, operating cash flow −$39.8M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $19.2M | $3.7M | $15.5M | +418% |
| Other income, net | $28.0M | $729K | $27.3M | 38× |
| Net loss | $17.4M | $64.1M | −$46.7M | -73% |
| Costs & expenses | $64.6M | $68.6M | −$4.0M | -6% |
| Operating costs | $63.4M | $68.6M | −$5.2M | -8% |
| Income tax | $1.2M | $0 | $1.2M | — |
| Research & development | $39.4M | $41.7M | −$2.3M | -6% |
| SG&A | $24.0M | $26.9M | −$2.9M | -11% |
| Operating cash sources | $52.4M | $57.7M | −$5.3M | -9% |
| Depreciation & amortization | $67K | $59K | $8K | +14% |
| Share-based compensation | $12.5M | $18.4M | −$5.9M | -32% |
| Cash used in operations | $39.8M | $39.2M | $559K | +1% |
| Net loss absorbed | $17.4M | $64.1M | −$46.7M | -73% |
| Working capital & other | $35.0M | −$6.5M | $41.4M | — |
Questions
How much did NewAmsterdam Pharma Co N.V.'s revenue grow quarter over quarter in Q3 2026?
NewAmsterdam Pharma Co N.V.'s revenue rose $15.5M (+418%) from $3.7M in Q2 2026 to $19.2M in Q3 2026.